To evaluate the characteristics of blood glucose fluctuation and safety and efficacy of sitagliptin in end-stage type 2 diabetic nephropathy on peritoneal dialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004150

Enrollment

Unknown

Registered

2014-01-15

Start date

2014-02-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

2 groups:sitagliptin vs placebo

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Aged 18 years and more; Stable insulin therapy for at least 8 weeks; peritoneal dialysis for at least 8 weeks; expectation life for at least 6 months.

Exclusion criteria

Exclusion criteria: The history of renal transplantation; The history of malignant tumor; The infection of HIV, Aplastic Anemia, MDS; Not capable of long term follow-up; Patients require 4.25% GS peritoneal dialysis solution.

Design outcomes

Primary

Measure	Time frame
HbA1c;GA;CGMS;the residual renal function;cardiovascular events;UCG;	—

Countries

China

Contacts

Public ContactLI Yuxiu

Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

liyuxiu@medmail.com.cn+86 13581705295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026